Abstract: The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: A conductive composition includes a mono-acid hybrid that includes an unprotected, single reactive group. The mono-acid hybrid may include substantially non-reactive groups elsewhere such that the mono-acid hybrid is functional as a chain terminator. Methods and devices using the compositions are also disclosed.

Abstract: Apparatuses are provided that include a rifle stock. For example, in one embodiment the stock includes an upper portion. The upper portion includes a proximal end and a distal end. A front portion and a rear portion are connected to the proximal end and the distal end of the upper portion, respectively. A bottom portion is connected to the front portion and rear portion. A first sidewall and a second sidewall are connected to the upper portion, the front portion, the rear portion, and the bottom portion. A channel is provided between the first and second sidewall. The upper portion, the front portion, the rear portion, and the bottom portion further define the channel. The first and second sidewalls include openings for accessing a computer device residing in the channel.

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: An anchor apparatus, ground anchor system, and method of using a ground anchor system are provided. The anchor apparatus includes a base plate having a top surface and a substantially planar bottom surface, wherein the base plate has a plurality of picket-guide apertures formed therein between the top surface and the substantially planar bottom surface. At least one picket is removably positioned in at least a portion of the picket-guide apertures. An anchor portion is formed at a first end of the base plate, wherein the anchor portion has an anchor aperture formed through the first end of the base plate, the anchor portion further comprising a ground face surface proximate to the anchor aperture, wherein a distance between the top surface and the ground face surface is less than a distance between the top surface and the substantially planar bottom surface.

Abstract: A method and system for sharing a user interface of a first device with a second device and enabling a user of the second device to interact with the user interface via gestures received by the second device. The first device (e.g., a smartphone) can host an application and generate a graphical user interface, which it transmits to the second device (e.g., a tablet computer) for display by the second device. The second device can receive input from a user, such as a touch input via a touchscreen of the second device, and transmit a representation of the input to the first device for providing input to the application hosted by the first device.

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: A contiguous duct assembly has first and second ducts that share at least one common wall element. An expansion joint is formed at the end of the contiguous duct assembly using a connector element that extends with respective portions into the internal spaces of the first and second ducts. First and second expansion fabrics are coupled to the respective portions from the inside of the ducts using fasteners that are accessible from and disposed within the internal space of the first and second ducts.

Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

Abstract: A conductive composition includes a mono-acid hybrid that includes an unprotected, single reactive group. The mono-acid hybrid may include substantially non-reactive groups elsewhere such that the mono-acid hybrid is functional as a chain terminator. Methods and devices using the compositions are also disclosed.

Abstract: An anchor apparatus, ground anchor system, and method of using a ground anchor system are provided. The anchor apparatus includes a base plate having a top surface and a substantially planar bottom surface, wherein the base plate has a plurality of picket-guide apertures formed therein between the top surface and the substantially planar bottom surface. At least one picket is removably positioned in at least a portion of the picket-guide apertures. An anchor portion is formed at a first end of the base plate, wherein the anchor portion has an anchor aperture formed through the first end of the base plate, the anchor portion further comprising a ground face surface proximate to the anchor aperture, wherein a distance between the top surface and the ground face surface is less than a distance between the top surface and the substantially planar bottom surface.